Crinetics Pharmaceuticals 향후 성장

Future 기준 점검 2/6

Crinetics Pharmaceuticals (는) 각각 연간 54.2% 및 56% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 53.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -28% 로 예상됩니다.

핵심 정보

54.2%

이익 성장률

53.26%

EPS 성장률

Pharmaceuticals 이익 성장	24.5%
매출 성장률	56.0%
향후 자기자본이익률	-27.97%
애널리스트 커버리지	Good
마지막 업데이트	21 Aug 2026

최근 향후 성장 업데이트

업데이트 없음

Recent updates

이익 및 매출 성장 예측

DB:6Z4 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	436	-286	-220	-339	7
12/31/2027	180	-463	-361	-367	12
12/31/2026	77	-507	-418	-391	12
6/30/2026	42	-502	-425	-423	N/A
3/31/2026	18	-496	-420	-414	N/A
12/31/2025	8	-465	-384	-378	N/A
9/30/2025	2	-423	-354	-348	N/A
6/30/2025	1	-370	-310	-304	N/A
3/31/2025	1	-328	-270	-266	N/A
12/31/2024	1	-298	-234	-230	N/A
9/30/2024	1	-278	-206	-202	N/A
6/30/2024	1	-259	-187	-180	N/A
3/31/2024	2	-235	-184	-178	N/A
12/31/2023	4	-215	-173	-169	N/A
9/30/2023	5	-199	-167	-163	N/A
6/30/2023	5	-184	-161	-160	N/A
3/31/2023	4	-175	-144	-142	N/A
12/31/2022	5	-164	-117	-115	N/A
9/30/2022	5	-150	-104	-103	N/A
6/30/2022	5	-136	-91	-90	N/A
3/31/2022	4	-119	-82	-82	N/A
12/31/2021	1	-108	-89	-89	N/A
9/30/2021	N/A	-98	-82	-82	N/A
6/30/2021	N/A	-89	-74	-74	N/A
3/31/2021	N/A	-79	-70	-70	N/A
12/31/2020	0	-74	-62	-62	N/A
9/30/2020	0	-67	-60	-60	N/A
6/30/2020	1	-63	-55	-55	N/A
3/31/2020	1	-59	N/A	-52	N/A
12/31/2019	1	-50	N/A	-46	N/A
9/30/2019	2	-44	N/A	-39	N/A
6/30/2019	2	-38	N/A	-31	N/A
3/31/2019	2	-31	N/A	-23	N/A
12/31/2018	2	-27	N/A	-19	N/A
9/30/2018	2	-21	N/A	-16	N/A
6/30/2018	2	-16	N/A	-13	N/A
3/31/2018	2	-12	N/A	-11	N/A
12/31/2017	2	-9	N/A	-9	N/A
12/31/2016	1	-6	N/A	-5	N/A

애널리스트 향후 성장 전망

수입 대 저축률: 6Z4 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: 6Z4 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: 6Z4 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: 6Z4 의 수익(연간 56%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: 6Z4 의 수익(연간 56%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: 6Z4는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/08/21 06:23
종가	2026/08/21 00:00
수익	2026/06/30
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Crinetics Pharmaceuticals, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Brian Skorney	Baird
Joshua Schimmer	Cantor Fitzgerald & Co.
David Lebowitz	Citigroup Inc

Crinetics Pharmaceuticals 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Recent updates

Second quarter 2026 earnings released: US$1.15 loss per share (vs US$1.23 loss in 2Q 2025)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX) for $9.2 billion.

Crinetics Pharmaceuticals, Inc. to Report Q2, 2026 Results on Aug 04, 2026

New minor risk - Share price stability

Crinetics Pharmaceuticals Announces Long-Term Data for Palsonify in Acromegaly Control

Crinetics Pharmaceuticals Presents Full Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia at ENDO 2026

Crinetics Pharmaceuticals Presents Six Abstracts Featuring Palsonify And Atumelnant At Endocrine Society Annual Meeting ENDO 2026

Insufficient new directors

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026

Crinetics Pharmaceuticals, Inc. Announces European Commission Approval of PALSONIFY for Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026

Crinetics Pharmaceuticals Submits Marketing Authorization Application for Palsonify in Brazil

Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026

Crinetics Pharmaceuticals, Inc. Approves Change in Title and Responsibilities for Jeff Knight, from Chief Operating Officer to Chief Development and Operating Officer, Effective January 2, 2026

Crinetics Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $350.139 million.

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Crinetics Pharmaceuticals, Inc. Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals, Inc. Announces Resignation of Dana Pizzuti as Chief Medical and Development Officer, Effective from December 31, 2025

Crinetics Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Crinetics Pharmaceuticals, Inc. Announces First Patient Randomized in Pivotal Phase 3 CarefDR Trial Evaluating Paltusotine in Carinoid Syndrome

Crinetics Pharmaceuticals, Inc. to Highlight Neuroendocrine Tumor Research Progress At the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Crinetics Pharmaceuticals, Inc. Announces FDA Approval of Palsonify™? (Paltusotine) for the Treatment of Adults with Acromegaly

Crinetics Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals, Inc. to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral Palsonify™? (Paltusotine) in Acromegaly At Endocrine Society

Crinetics Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Crinetics Pharmaceuticals, Inc. to Showcase the Next Generation of Endocrinology Innovation At Endocrine Society's Annual Meeting, ENDO 2025

Crinetics Pharmaceuticals, Inc. to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment At the American Association of Clinical Endocrinology Annual Meeting 2025

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2025

Crinetics Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 08, 2025

Crinetics Pharmaceuticals, Inc. Appoints Tobin “Toby” Schilke as Chief Financial Officer, Effective February 28, 2025

Crinetics Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Crinetics Announces Positive Topline Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)

Crinetics Pharmaceuticals, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer

Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Second quarter 2024 earnings released: US$0.94 loss per share (vs US$0.94 loss in 2Q 2023)

Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer

Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from Russell 2500 Value Index

Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Crinetics Pharmaceuticals, Inc. Appoints Robert M. Cuddihy as Senior Vice President of Medical Affairs

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

First quarter 2024 earnings released: US$0.93 loss per share (vs US$0.85 loss in 1Q 2023)

Crinetics Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Full year 2023 earnings released: US$3.69 loss per share (vs US$3.15 loss in FY 2022)

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Third quarter 2023 earnings released: US$1.01 loss per share (vs US$0.78 loss in 3Q 2022)

New minor risk - Shareholder dilution

Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.81 loss in 2Q 2022)

Founder recently sold €903k worth of stock

Founder recently sold €952k worth of stock

Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023

Chief Development Officer recently sold €121k worth of stock

Crinetics Pharmaceuticals, Inc. Provides Update on Crn04777 Program

High number of new directors

Crinetics Pharmaceuticals, Inc. Completes Enrollment in Phase 3 PATHFNDR-1 Study

Crinetics Pharmaceuticals, Inc Announces that Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

Crinetics Pharmaceuticals Appoints Dana Pizzuti as Chief Development Officer

Crinetics Pharmaceuticals Announces New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

High number of new and inexperienced directors

Crinetics Pharmaceuticals, Inc. Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

High number of new and inexperienced directors